X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 24.6 - View Chart
P/BV x 6.2 3.6 173.4% View Chart
Dividend Yield % 0.7 0.6 108.7%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-17
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589842 188.7%   
Low Rs1,232572 215.2%   
Sales per share (Unadj.) Rs417.5131.6 317.2%  
Earnings per share (Unadj.) Rs56.332.7 172.1%  
Cash flow per share (Unadj.) Rs64.738.0 170.4%  
Dividends per share (Unadj.) Rs12.703.50 362.9%  
Dividend yield (eoy) %0.90.5 181.9%  
Book value per share (Unadj.) Rs292.9152.7 191.8%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.4 62.9%   
Avg P/E ratio x25.121.6 115.9%  
P/CF ratio (eoy) x21.818.6 117.0%  
Price / Book Value ratio x4.84.6 104.0%  
Dividend payout %22.610.7 210.8%   
Avg Mkt Cap Rs m168,6531,696,877 9.9%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m9,17149,023 18.7%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m49,915315,784 15.8%  
Other income Rs m1,6456,232 26.4%   
Total revenues Rs m51,561322,016 16.0%   
Gross profit Rs m8,482100,893 8.4%  
Depreciation Rs m1,00612,648 8.0%   
Interest Rs m6713,998 16.8%   
Profit before tax Rs m8,45190,479 9.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60612,116 13.3%   
Profit after tax Rs m6,73178,462 8.6%  
Gross profit margin %17.031.9 53.2%  
Effective tax rate %19.013.4 141.9%   
Net profit margin %13.524.8 54.3%  
BALANCE SHEET DATA
Current assets Rs m27,062329,537 8.2%   
Current liabilities Rs m15,324178,870 8.6%   
Net working cap to sales %23.547.7 49.3%  
Current ratio x1.81.8 95.9%  
Inventory Days Days6779 84.2%  
Debtors Days Days4183 49.6%  
Net fixed assets Rs m12,610204,766 6.2%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m34,490363,997 9.5%   
Net worth Rs m35,027366,397 9.6%   
Long term debt Rs m1,21214,361 8.4%   
Total assets Rs m54,387614,102 8.9%  
Interest coverage x13.623.6 57.6%   
Debt to equity ratio x00 88.3%  
Sales to assets ratio x0.90.5 178.5%   
Return on assets %13.613.4 101.4%  
Return on equity %19.221.4 89.7%  
Return on capital %24.924.8 100.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56344,118 14.9%   
Fx outflow Rs m3,01224,484 12.3%   
Net fx Rs m3,55219,634 18.1%   
CASH FLOW
From Operations Rs m7,25970,822 10.2%  
From Investments Rs m1,864-42,216 -4.4%  
From Financial Activity Rs m-9,273-22,854 40.6%  
Net Cashflow Rs m-1506,107 -2.5%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Share Markets in India End Flat; Cipla & Bharti Airtel Top Gainers(Closing)

Share markets in India ended flat ahead of key corporate results and as profit booking in index heavyweights capped gains.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

More Views on News

Most Popular

25 Things PM Modi Did Not Tell You About the Indian Economy(Vivek Kaul's Diary)

Oct 9, 2017

There are way too many data points out there which clearly show that all is not well with the Indian economy.

The Multibaggers that will Rise from the Ashes of Disruption(Smart Contrarian)

Oct 4, 2017

Of new age asset-light businesses and an Indian player that ticks all the right boxes.

Invest in a 'Haunted House' Stock and Make a Killing(The 5 Minute Wrapup)

Oct 7, 2017

You can make a killing by buying non-commodity business in a commodity industry

Nifty 50 Constituents Change...Once Again(Daily Profit Hunter)

Oct 4, 2017

Does it make sense to look at long term charts when the index constituents are changing frequently?

BSE IPO Index vis-a-vis Sensex(Chart Of The Day)

Oct 7, 2017

IPO's have failed to beat the benchmark index in the past decade.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Oct 17, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS